Activating ESR1 mutations differentially impact the efficacy of ER antagonists

Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer (MBC) and found some of them to promote estrogen-independent activation of the receptor. The degree to which all recurrent mutants can drive estrogen-independent activities and reduced sensitivity to ER a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Discov
Auteurs principaux: Toy, Weiyi, Weir, Hazel, Razavi, Pedram, Lawson, Mandy, Goeppert, Anne U, Mazzola, Anne Marie, Smith, Aaron, Wilson, Joanne, Morrow, Christopher, Wong, Wai Lin, De Stanchina, Elisa, Carlson, Kathryn E., Martin, Teresa S., Uddin, Sharmeen, Li, Zhiqiang, Fanning, Sean, Katzenellenbogen, John A., Greene, Geoffrey, Baselga, Jośe, Chandarlapaty, Sarat
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5340622/
https://ncbi.nlm.nih.gov/pubmed/27986707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1523
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires